C11orf80 Inhibitors
C11orf80 inhibitors include a variety of compounds that indirectly diminish the functional activity of C11orf80 through the inhibition of specific signaling pathways or biological processes in which it may be involved. Wortmannin and LY294002 are potent inhibitors of PI3K, a key regulator of the AKT pathway, which is crucial for many cellular processes including metabolism, survival, and growth. Inhibition of this pathway could result in decreased functional activity of C11orf80 if it is contingent upon PI3K/AKT signaling. Rapamycin specifically targets mTORC1, a downstream effector in the AKT pathway, and its inhibition could also reduce the activity of C11orf80 if it operates within this pathway.
MEK inhibitors such as PD98059 and U0126 would lead to diminished activity of C11orf80 by preventing the activation of the ERK1/2 pathway, which is involved in cell proliferation and differentiation. JNK and p38 MAPK are other mitogen-activated protein kinases that regulate apoptosis and inflammation, respectively. SP600125 and SB203580, as specific inhibitors of these kinases, would decrease C11orf80 activity if it is regulated by either of these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that blocks the PI3K/AKT pathway. C11orf80, if involved in this pathway, would have its functional activity decreased due to the prevention of AKT phosphorylation, which is crucial for its activation and subsequent cell survival and proliferation signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor that prevents AKT activation by inhibiting its upstream regulator PI3K. If C11orf80 activity is enhanced by PI3K/AKT signaling, the inhibition of this pathway would result in decreased activity of C11orf80. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An inhibitor of the mammalian target of rapamycin (mTOR) that binds to FKBP12 and blocks mTORC1. Since mTORC1 is downstream of AKT, inhibition by Rapamycin could lead to decreased activity of C11orf80 if it is part of the mTOR signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that blocks the activation of ERK1/2. If C11orf80 function is related to the MAPK/ERK pathway, blocking this pathway would decrease its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinases (JNKs) that would diminish C11orf80 activity if the protein is regulated by JNK signaling which is involved in controlling apoptosis and cell differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor which would decrease C11orf80 activity by inhibiting p38 MAPK-mediated signaling pathways if C11orf80 is regulated by these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2 preventing ERK1/2 activation. A decrease in C11orf80 activity would result if it is functionally linked to the MEK/ERK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor which would lead to reduced activity of C11orf80 if it is involved in signaling pathways that are dependent on Src kinase-mediated phosphorylation events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor that, by blocking Src family kinases, could decrease the activity of C11orf80 if it relies on Src kinase signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A RAF kinase inhibitor which also inhibits VEGFR and PDGFR. If C11orf80 functions are linked to the RAF/MEK/ERK signaling cascade, its activity would be reduced by Sorafenib. | ||||||